Advertisement
Screener

TENAX THERAPEUTICS, INC. (TENX) Impairment of Long-Lived Assets Held-for-use

2.0 / 5 stars · 17/43 Roast Me

TENAX THERAPEUTICS, INC. Impairment of Long-Lived Assets Held-for-use

TENAX THERAPEUTICS, INC. (TENX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-04-02.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2018-04-02

  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2015-06-30 was $1.03M.
  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2014-04-30 was $0.00, a 100.00% decline year-over-year.
  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for the quarter ending 2014-01-31 was $0.00.
  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2016 was $33.27M.
  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2015 was $1.03M.
  • TENAX THERAPEUTICS, INC. impairment of long-lived assets held-for-use for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
Period endImpairment of Long-Lived Assets Held-for-use 3 monthImpairment of Long-Lived Assets Held-for-use 6 monthImpairment of Long-Lived Assets Held-for-use 8 monthImpairment of Long-Lived Assets Held-for-use 9 monthImpairment of Long-Lived Assets Held-for-use 12 monthImpairment of Long-Lived Assets Held-for-use 530 monthImpairment of Long-Lived Assets Held-for-use 533 monthImpairment of Long-Lived Assets Held-for-use 536 monthImpairment of Long-Lived Assets Held-for-use 539 monthImpairment of Long-Lived Assets Held-for-use 542 monthImpairment of Long-Lived Assets Held-for-use 545 monthImpairment of Long-Lived Assets Held-for-use 554 monthImpairment of Long-Lived Assets Held-for-use 557 month
2017-12-31$0.00
10-K · filed 2018-04-02
2016-12-31$33.27M
10-K · filed 2018-04-02
2016-06-30$0.00
10-Q · filed 2016-08-09
$0.00
10-Q · filed 2016-08-09
2015-12-31$0.00
10-K · filed 2017-03-16
2015-06-30$1.03M
10-Q · filed 2016-08-09
$1.03M
10-Q · filed 2016-08-09
2015-04-30$1.03M
10-K · filed 2017-03-16
2014-04-30$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16
$0.00
derived: sum of 2 quarters · filed 2017-03-16
$0.00
derived: sum of 3 quarters · filed 2017-03-16
$0.00
10-K · filed 2017-03-16
2014-01-31$0.00
10-Q · filed 2014-03-17
$0.00
derived: sum of 2 quarters · filed 2014-03-17
$0.00
10-Q · filed 2014-03-17
$390.97K
10-Q · filed 2014-03-17
2013-10-31$0.00
10-Q · filed 2013-12-17
$0.00
10-Q · filed 2013-12-17
$390.97K
10-Q · filed 2013-12-17
2013-07-31$390.97K
10-Q · filed 2013-09-17
2013-04-30$27.28K
derived: 10-KT 12 month − 10-Q 9 month · filed 2016-03-14
$27.28K
derived: sum of 2 quarters · filed 2016-03-14
$27.28K
derived: sum of 3 quarters · filed 2016-03-14
$27.28K
10-KT · filed 2016-03-14
$390.97K
10-K · filed 2013-06-26
2013-01-31$0.00
10-Q · filed 2014-03-17
$0.00
derived: sum of 2 quarters · filed 2014-03-17
$0.00
10-Q · filed 2014-03-17
$363.69K
10-Q · filed 2013-03-18
2012-10-31$0.00
10-Q · filed 2013-12-17
$0.00
10-Q · filed 2013-12-17
$363.69K
10-Q · filed 2012-12-14
2012-07-31$363.69K
10-Q · filed 2012-09-19
2012-04-30$29.53K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-06-26
$29.53K
derived: sum of 2 quarters · filed 2013-06-26
$29.53K
derived: sum of 3 quarters · filed 2013-06-26
$29.53K
10-K · filed 2013-06-26
$363.69K
10-K · filed 2012-07-25
2012-01-31$0.00
10-Q · filed 2012-03-15
$0.00
derived: sum of 2 quarters · filed 2012-03-15
$0.00
10-Q · filed 2012-03-15
$302.04K
derived: sum of 4 quarters · filed 2012-07-25
$334.16K
10-Q · filed 2012-03-15
2011-10-31$0.00
10-Q · filed 2011-12-15
$0.00
10-Q · filed 2011-12-15
$302.04K
derived: sum of 3 quarters · filed 2012-07-25
$302.04K
derived: sum of 4 quarters · filed 2012-07-25
$334.16K
10-Q · filed 2011-12-15
2011-07-31$0.00
10-Q · filed 2011-09-19
$302.04K
derived: sum of 2 quarters · filed 2012-07-25
$302.04K
derived: sum of 3 quarters · filed 2012-07-25
$302.04K
derived: sum of 4 quarters · filed 2012-07-25
$334.16K
10-Q · filed 2011-09-19
2011-04-30$302.04K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-25
$302.04K
derived: sum of 2 quarters · filed 2012-07-25
$302.04K
derived: sum of 3 quarters · filed 2012-07-25
$302.04K
10-K · filed 2012-07-25
2011-01-31$0.00
10-Q · filed 2012-03-15
$0.00
derived: sum of 2 quarters · filed 2012-03-15
$0.00
10-Q · filed 2012-03-15
2010-10-31$0.00
10-Q · filed 2011-12-15
$0.00
10-Q · filed 2011-12-15
2010-07-31$0.00
10-Q · filed 2011-09-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
Yarrow Bioscience, Inc. (YARW)United States$0.070B
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17
Cingulate Inc. (CING)United States$0.073B-2.64
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
XBiotech Inc. (XBIT)United States$0.066B-1.56
OS Therapies Inc (OSTX)United States$0.076B-2.17